Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ...
About Orchestra BioMed Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical ...
The disclosure reveals a tax-related share withholding event by Joshua Aiello, Principal Accounting Officer of Orchestra ...
Andrew Lawrence Taylor, Chief Financial Officer of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) OBIO (NASDAQ:OBIO) , ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, /PRNewswire/ -- Harbour BioMed (the 'Company'; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ...
Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...
The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary ...
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, ...
BioMed Realty Trust continues to push the life sciences conversion wave in Boston, quietly taking over two prominent development sites. The Blackstone-backed life sciences investor has entered a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results